Bedrijfsoverzicht
10x Genomics, Inc. is a specialized provider within the healthcare sector that develops and sells instruments, consumables, and software designed for the analysis of biological systems across the United States, the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. Operating specifically within the Health Information Services industry, the company focuses on delivering the Chromium platform and a single cell portfolio to enable advanced biological research and commercial applications. The organization employs a workforce of 1,178 individuals, reflecting a substantial operational footprint in the life sciences technology landscape. With a market capitalization of $2.97 billion and annual revenue of $642.82 million, the company holds a significant valuation that suggests strong investor confidence in its technological capabilities and market penetration, positioning it as a key player in the genomic data analysis infrastructure.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $642.82 million, yet it recorded a net income loss of $-43,544,000 and an EBITDA of $-64,086,000, indicating a substantial gap between top-line growth and bottom-line profitability that points to high operating costs and capital expenditures associated with R&D and manufacturing. Despite the accounting losses, the firm generated free cash flow of $148.39 million, which provides critical financial flexibility by allowing the company to fund its growth initiatives, repay obligations, or return capital without immediate reliance on external financing. The gross margin stands at 69.1%, demonstrating strong pricing power and efficient production costs relative to revenue, whereas the operating margin of -9.4% and profit margin of -6.8% reveal that significant operational expenses and non-operating items are currently outweighing gross profits. On the balance sheet, the company holds $523.41 million in cash against $84.36 million in debt, resulting in a debt-to-equity ratio of 10.59, which suggests a highly leveraged structure relative to equity but is mitigated by the substantial cash reserve. The current ratio of 4.46 indicates a robust short-term liquidity position, ensuring the company can comfortably meet its obligations as they come due. Furthermore, the return on equity is -5.8% and the return on assets is -6.4%, metrics that reveal management has yet to generate positive returns on the capital invested, a common characteristic for high-growth biotechnology firms still scaling their operations.
Waarderingsbeoordeling
The valuation metrics present a complex picture, with a trailing P/E ratio of N/A due to the lack of earnings and a forward P/E of 139.62, which implies that the market expects significant earnings growth in the coming years to justify the current price. The price-to-book ratio is 3.73, indicating that the market values the company at a substantial premium over its book value, reflecting the high intangible assets and intellectual property inherent in the genomic technology sector. Alternative valuation measures such as a price-to-sales ratio of 4.62 and an EV/EBITDA of -39.54 suggest that the stock is priced heavily on future revenue potential rather than current profitability. The stock has experienced significant volatility over the past year, trading between a 52-week high of $23.65 and a 52-week low of $7.25, with the current price situated well below the recent highs as the market digests the valuation multiple. The beta of 2.17 indicates that the stock's price volatility is more than twice that of the broader market, making it a high-risk, high-potential-reward investment sensitive to shifts in investor sentiment regarding healthcare technology.
Growth & Income
Revenue growth year-over-year stands at 0.6%, while earnings growth is N/A due to the company's ongoing losses, implying that top-line expansion is currently outpacing any potential earnings generation. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are theoretically reinvested into growth initiatives rather than distributed to shareholders. This reinvestment strategy is typical for firms in the developmental stage of their lifecycle, prioritizing market share acquisition and product development over immediate income distribution. The overall growth and income profile is characterized by modest revenue expansion and a total absence of dividend income, relying entirely on capital appreciation potential to provide returns to investors.